• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Pharmacotherapy and Mortality in Chronic Obstructive Pulmonary Disease.

作者信息

Halpin David M G, Martinez Fernando J

机构信息

University of Exeter Medical School, College of Medicine and Health, University of Exeter, Exeter, United Kingdom; and.

NewYork-Presbyterian Hospital/Weill Cornell Medical Center, New York, New York.

出版信息

Am J Respir Crit Care Med. 2022 Nov 15;206(10):1201-1207. doi: 10.1164/rccm.202205-1000PP.

DOI:10.1164/rccm.202205-1000PP
PMID:35901121
Abstract
摘要

相似文献

1
Pharmacotherapy and Mortality in Chronic Obstructive Pulmonary Disease.慢性阻塞性肺疾病的药物治疗与死亡率
Am J Respir Crit Care Med. 2022 Nov 15;206(10):1201-1207. doi: 10.1164/rccm.202205-1000PP.
2
Spirometric Criteria for Chronic Obstructive Pulmonary Disease in Clinical Trials of Pharmacotherapy.药物治疗临床试验中慢性阻塞性肺疾病的肺量计标准
COPD. 2018 Feb;15(1):17-20. doi: 10.1080/15412555.2018.1424815.
3
Comparison of the 2017 and 2015 Global Initiative for Chronic Obstructive Lung Disease Reports. Impact on Grouping and Outcomes.2017 年和 2015 年全球慢性阻塞性肺疾病倡议报告比较。对分组和结果的影响。
Am J Respir Crit Care Med. 2018 Feb 15;197(4):463-469. doi: 10.1164/rccm.201707-1363OC.
4
Respiratory pharmacotherapy use in patients newly diagnosed with chronic obstructive pulmonary disease in a primary care setting in the UK: a retrospective cohort study.英国基层医疗环境中初诊慢性阻塞性肺疾病患者的呼吸药物治疗使用情况：一项回顾性队列研究
COPD. 2014 Sep;11(5):521-30. doi: 10.3109/15412555.2014.922064. Epub 2014 Jun 19.
5
Commentary on "Costs of pharmacotherapy of chronic obstructive pulmonary disease in relation to changing Global Initiative for Chronic Obstructive Lung Disease guidelines (2007, 2011, and 2017 updates)".关于“慢性阻塞性肺疾病药物治疗成本与全球慢性阻塞性肺疾病倡议指南（2007年、2011年及2017年更新版）变化的关系”的述评
Pol Arch Intern Med. 2019 May 31;129(5):299-300. doi: 10.20452/pamw.14856.
6
[Use of antibiotics in the exacerbation of chronic obstructive pulmonary disease].[抗生素在慢性阻塞性肺疾病急性加重期的应用]
Rev Esp Quimioter. 2001 Mar;14(1):87-96.
7
Corticosteroid administration and treatment failure in acute exacerbation of chronic obstructive pulmonary disease.慢性阻塞性肺疾病急性加重期的皮质类固醇给药与治疗失败
JAMA. 2010 Oct 13;304(14):1554; author reply 1554-6. doi: 10.1001/jama.2010.1438.
8
Severity of airflow limitation, co-morbidities and management of chronic obstructive pulmonary disease patients acutely admitted to hospital.急性住院的慢性阻塞性肺疾病患者的气流受限严重程度、合并症和管理。
Hong Kong Med J. 2013 Dec;19(6):498-503. doi: 10.12809/hkmj133909. Epub 2013 Jun 20.
9
[Antimicrobial treatment of exacerbation in chronic obstructive pulmonary disease: 2007 consensus statement].[慢性阻塞性肺疾病急性加重期的抗菌治疗：2007年共识声明]
Arch Bronconeumol. 2008 Feb;44(2):100-8. doi: 10.1016/s1579-2129(08)60013-0.
10
Compliance of Pharmacotherapy with GOLD Guidelines: A Longitudinal Study in Patients with COPD.《COPD 患者药物治疗与 GOLD 指南的一致性：一项纵向研究》。
Int J Chron Obstruct Pulmon Dis. 2020 Mar 26;15:627-635. doi: 10.2147/COPD.S240444. eCollection 2020.

引用本文的文献

1
Increasing Quality and Quantity of Life in Individuals with Chronic Obstructive Pulmonary Disease: A Narrative Review with an Emphasis on Pulmonary Rehabilitation.提高慢性阻塞性肺疾病患者的生活质量和数量：一篇侧重于肺康复的叙述性综述
Life (Basel). 2025 May 7;15(5):750. doi: 10.3390/life15050750.
2
Epidemiology and SARIMA model of deaths in a tertiary comprehensive hospital in Hangzhou from 2015 to 2022.2015 年至 2022 年杭州市某三级综合医院死亡病例的流行病学及 SARIMA 模型分析。
BMC Public Health. 2024 Sep 19;24(1):2549. doi: 10.1186/s12889-024-20033-7.
3
An Italian Delphi Consensus on the Triple inhalation Therapy in Chronic Obstructive Pulmonary Disease.
意大利慢性阻塞性肺疾病三联吸入疗法德尔菲共识
Multidiscip Respir Med. 2024 Sep 18;19(1):949. doi: 10.5826/mrm.2024.949.
4
Exacerbation history and blood eosinophil count prior to diagnosis of COPD and risk of subsequent exacerbations.在 COPD 诊断之前的加重病史和血嗜酸性粒细胞计数与随后的加重风险。
Eur Respir J. 2024 Oct 3;64(4). doi: 10.1183/13993003.02240-2023. Print 2024 Oct.
5
Risk factors of acute exacerbation and disease progression in young patients with COPD.慢性阻塞性肺疾病（COPD）年轻患者急性加重和疾病进展的危险因素
BMJ Open Respir Res. 2024 Jul 17;11(1):e001740. doi: 10.1136/bmjresp-2023-001740.
6
Current Perspectives of Pharmacotherapies for COPD.COPD 的药物治疗现状。
Respir Care. 2023 Jul;68(7):927-938. doi: 10.4187/respcare.10952.
7
Causes of and Clinical Features Associated with Death in Tobacco Cigarette Users by Lung Function Impairment.因肺功能损伤导致的烟草使用者死亡的原因和相关临床特征。
Am J Respir Crit Care Med. 2023 Aug 15;208(4):451-460. doi: 10.1164/rccm.202210-1887OC.